ReviveMed
Private Company
Total funding raised: $2.5M
Overview
ReviveMed is a private, pre-revenue biotech company founded in 2017, commercializing an AI and machine learning platform for metabolomics. Its core technology, developed at MIT, addresses key challenges in metabolite signal detection and annotation, enabling the creation of generative models and virtual patient simulations. The company is initially targeting precision obesity and precision oncology, specifically aiming to predict patient response to cancer immunotherapies and better assess metabolic disease risk beyond traditional metrics.
Technology Platform
Patented AI-based platform for large-scale metabolomics. It includes mzLearn for parameter-free LC/MS signal detection and drift correction, knowledge-based graphs for metabolite annotation, and generative models to create digital metabolic twins for simulating disease and treatment response.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
ReviveMed competes in the crowded AI/ML drug discovery sector against companies like Recursion and Exscientia, but its deep focus on metabolomics is a key differentiator. It also faces competition from diagnostic companies developing liquid biopsies and from internal efforts at large pharma and tech companies. Its academic foundation and specialized platform are its primary competitive advantages.